Source comparison
Comparison of Gastric Protection Mechanisms: BPC-157 vs Standard Therapies
Research models allow direct mechanistic comparison between BPC-157 and conventional gastric protective agents. The table below summarizes documented mechanisms, limitations, and research applications for each therapeutic class. BPC-157 Angiogenesis, NO modula
This comparison does not assign a generated winner or score.
- Research models allow direct mechanistic comparison between BPC-157 and conventional gastric protective agents. The table below summarizes documented mechanisms, limitations, and research applications for each therapeutic class.
- BPC-157
- Angiogenesis, NO modulation, growth factor activation
- 50–72% lesion reduction in ethanol/NSAID models; accelerated healing timeline
- Mechanisms incompletely characterized; limited large animal data; no FDA-approved formulation
- Ideal for studying active tissue regeneration mechanisms beyond acid suppression alone
- Proton Pump Inhibitors
- Irreversible H+/K+-ATPase inhibition → acid suppression
- 30–45% lesion reduction in acid-dependent models; minimal effect in ethanol models
- Does not accelerate healing in non-acid-mediated injury; no direct angiogenic effect
- Limited research value for non-acid injury mechanisms
- H2 Receptor Antagonists
- Competitive histamine receptor blockade → reduced acid secretion
- 25–40% lesion reduction in stress models; inconsistent in NSAID models
- Weaker acid suppression than PPIs; tolerance develops within 2 weeks
- Useful for histamine pathway research but limited for tissue regeneration studies
- Prostaglandin Analogs
- PGE1 receptor agonism → mucus/bicarbonate secretion, mucosal blood flow
- 35–50% lesion reduction in NSAID models; protects against aspirin injury
- Mechanism-dependent (requires intact prostaglandin pathway); GI side effects limit dosing
- Strong research tool for prostaglandin-dependent protection pathways
- Sucralfate
- Physical barrier formation; growth factor binding at ulcer sites
- 20–35% lesion reduction in acid-pepsin models; minimal systemic effects
- Requires acidic pH to activate; no effect in ethanol models; does not reduce inflammation
- Limited to acid-dependent injury models; poor systemic bioavailability